Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
A world without disease: Janssen - Flanders.bio partner day 2018

A new vision was in the spotlight at the Flanders.bio - Janssen Pharmaceutica Partner Day this year. “A world without disease” was the slogan on e…


Nanobodies®: small magical molecules for big difficult diseases

One of Belgium’s established biotech companies, Ablynx, has developed an innovative platform to produce small therapeutic proteins, called Nanobod…


Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Ghent, Belgium, and Dresden, Germany - 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a dr…

POPULAR TAGS

John Berriman heads the Confo Therapeutics board

Written by LVS on in the category news with the tags , , .


GPCR drug designer Confo Therapeutics has announced that John Berriman was appointed as Chairman of the Board. Berriman is a known biotech veteran and has served on the boards of many biotech companies, including stem cell play ReNeuron and immunotherapeutics specialist Autolus. Most notably, Berriman was Chairman of Heptares Therapeutics, another company exclusively focused on GPCR drug development. Berriman’s insight and experience in the GPCR space will no doubt be most valuable to Confo.

Confo CEO Cedric Ververken showed great enthusiasm on the matter: “We are delighted to have attracted someone of John Berriman’s calibre to serve as Chairman of our company. John has a very impressive track record in founding, financing and growing biotech companies and his appointment is a huge asset to Confo Therapeutics as it further transitions from a technology to a drug discovery company,”

Read all Confo Therapeutics news

“I am delighted to be joining and chairing the board of Confo Therapeutics, whose technology is, I believe, one of the industry’s most promising platforms for cracking currently undruggable GPCRs, especially when an agonist is required,” Berriman commented. “I look forward to working with the board and the management team and contributing to the company’s continued evolution and growth.”

RELATED ARTICLES
A world without disease: Janssen - Flanders.bio partner day 2018

A new vision was in the spotlight at the Flanders.bio - Janssen Pharmaceutica Partner Day this year. “A world without disease” was the slogan on e…


Nanobodies®: small magical molecules for big difficult diseases

One of Belgium’s established biotech companies, Ablynx, has developed an innovative platform to produce small therapeutic proteins, called Nanobod…


Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Ghent, Belgium, and Dresden, Germany - 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a dr…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin Itera Life Science GSK KU Leuven V-Bio Ventures UGent Turnstone Flanders.bio Janssen XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.